Launched in 2021, the Fast-Track for COVID-19 Related Appeals Pilot Program provided for appellants to petition for expedited consideration of an ex parte appeal of a rejection of claims to a product or process relating to COVID‑19 (subject to applicable US Food and Drug Administration approval). The petition is without a fee.
The USPTO recently announced termination of the program, effective April 16, 2026.
Petitions filed prior to the April 16 deadline will continue to be processed and will retain its fast-track status.
Appellants interested in expediting ex parte appeals may still do so under the Fast-Track Appeals Pilot Program, which requires payment of a fee and has limited availability (125 petitions per quarter).